GlaxoSmithKline’s (GSK) former chief executive Andrew Witty was yesterday announced as the new CEO of Optum – a US payer organisation which includes pharmacy benefits manager OptumRx.
Prime Minister Theresa May set out a bold vision for the UK outside the European Union yesterday, confirming that the country would be leaving the single market – a move which most interpre
The US FDA announced today that it has cleared two novel gene therapies for sickle cell disease: Vertex Pharmaceuticals' Casgevy and bluebird bio's Lyfgenia.
On 1st October, the roll-out of the National Contract Value Review (NCVR) process marked a pivotal moment in the trajectory of clinical research in the UK, introducing a standardised, natio
